Drugs Imported From Ranbaxy Plant Barred From United States Entry
A Mohali, India-based plant will no longer be allowed to ship drugs approved by the Food and Drug Administration into the United States until such time that the plant is brought into line with current good manufacturing practices. The FDA put forth this import alert pertaining to a Ranbaxy plant after inspections from last year revealed that the company was not doing a proper job looking into issues with manufacturing or doing what was necessary to ensure that the quality of items was up to par. If officials spot drugs from this particular facility attempting to be brought into the country, they are allowed to detain those items. The company won’t be allowed to produce drugs approved by the FDA until such time that they can certify their compliance with regulations.
Click here for more information.